A new phosphate-binding agent which does not cause any severe side effects in vivo was developed by modifying a crosslinked dextran with polynuclear iron(III)oxide-hydroxide. Its particle size ranges from 150 to 300
Introduction
lopathy and osteomalacia. The use of calcium com-T , . 1jC ., , , . ,, pounds is associated with gastrointestinal problems such In chromc renal faüure phosphorus retentioii and hyper-,. ' .,, r . , ,. , . , ^, , , 4 . , · i · t 'j i * j äs diarrhoea or mild constipation and a high nsk of hypphosphataerma play a major role in the development and , . ^ ' *, . , , -, . , ~ , , ., .,. -ercalcaemia. The dosage of magnesium hydroxide äs an mamtenance of secondary hyperoarathyroidism and os-, . , , , . , . , . . , , teodystrophy (1) (2) (3) . Neitber an adequate diet nor effialt^atlve P hos P hate binder 1S hmited b y the serum cient dialysis are usually sufficient to prevent pathologic ««eneiiüm concentration. In addition, this agent alone phosphate concentrations in the blood (4) . Antacids such has P roved i°a de^ate ** the e " act contro1 of serum äs A1(OH) 3 or CaCO 3 possess the capacity to adsorb P^sphate (10) . Current therapies include reduction of Phosphate. However, aptacids presently used for that ^^ Phosphate intake, reduction of phosphate absorppurpose are quite inefficient in binding phosphate in tion in Äe intestine b y P h «sphate binding agents, and vivo, although aluminum-or calcium-containiag com-«öianqed removal of phosphate from the body through pounds are orälly administered in large amounts (5, 6) . »«>« efficient dialysis techniques. The recommended inThe inefficiency of cofnmonly-used phosphate binders take of phosphate should not exceed 32 mmol (1000 mg creates a clinical dilemma, since the control of hyperp ) P er da y in adults and should be reduced for children phösphataemia requires increased doses, which result in according to their age. With highly specialized diets, the a higher riskof toxieily. This includes bone disease, alu-intake of phosphorus can be reduced to less than 16 minum dementia from aluminum containing antacids (7, mmol (500 mg P) per day (11) . In patients with mildly 8), and hypercalcaemia, äs well äs soft tissue calcifica-increased serum phosphate concentrations, haemodialytion from antacids containing calcium (9) . The increased sis removes about 8 mmol (252 mg P) of phosphate per tissue content of aluminum appears to be an important day with three treatments per week. Continuous ambulafactor in the pathogenesis of dialysis-related encepha-tory peritoneal dialysis even removes about 10 mmol (324 mg P) per day (12) . These rates of removal, however, are still insufficient. Hence, most patients with end-stage renal failure require phosphate binders.
Recently we developed a novel phosphate-binding agent by coupling polynuclear iron(III) oxide-hydroxide to crosslinked dextran (13) . In addition to its oral application, this material has the potential to serve äs a phosphate adsorbent in extracorporeal perfusion Systems for the treatment of hype hosphataemia.
Materials and Methods

Preparation of phosphate adsorbent
Starting material for the preparation of an insoluble iron(III)oxidehydroxide porous support was the crosslinked dextran Dormagel N 25 C™ (Pfeifer and Langen, Dormagen, Germany). Dormagel™ is a spherical, neutral, soft gel cross-linked by epichlorhydrin. The molecular cut-off of the unmodified material corresponds to M r = 6000, and the particle size is 150-300
. The pH stability ranges from 2 to 12, and the swelling capacity is 4-6 ml/g. For chemieäl modiflcation according to I.e. (13) the material was suspended in a 50% solution of FeCla · 6 H 2 O. This mixture was then added under vigorous stirring to l mol/1 sodium hydroxide solution. The modified gel beads were collected by filtration and washed with water to neutrality. Sterilization was carried out at a temperature of 121 °C according to F 0 15 conditions üsing an autoclave (type GETING GEV 112) (14) . 
Test Solutions
Blood and plasma:
Fresh blood from pigs was obtained from the slaughter house in Melsungen and human blood was provided by the DRK blood bank, Kassel. For stabilization, heparin (6000 IU/1) was added. The blood was centrifuged for 10 min at 4500 min" 1 to separate blood cells from plasma.
Determination of enzymes and electrolytes
Enzyme activities of glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, lactate dehydrogenase, and alkaline phosphatase were determined according to Standard methods, described by Rick (15) . Phosphate, calcium, magnesium, iron, and protein concentrations in serum, plasma or aqueous Solutions were photometrically determined according to Standard protocols (16) (17) (18) .
The iron content of the adsorbent was determined by atomic absorption (AAS) (19) , and its phosphate concentration by indüc-tively coupled plasma spectroscopy (ICP) (20) .
Physical characterization
Scanning electron microscopy of the adsorbent was performed on a SEM XS 40 (ABT, Japan) at 20 kV. The magnification for the uncoated and the modified dextran beads was in the ränge of 100-3000-fold. Electron micrographs were taken with an Asanuma Camera (Mechanical Laboratory & Co, Japan) using a Polaroid Film Type 52 (400 ASA/27 DIN). ESCA (electron spectroscopy for chernical analysis), Mössbauer and magnetic measurements were kindly performed by Drs. J. Knecht and J. Pebler, Fachbereich Chemie, University of Marburg.
In vitro perfusion experiments
In vitro tests with Standard Solutions, plasma, or blood were carried put äs follows. Glass colurrins (Bip-Rad, 120 X 10 mm) were packed with 3 ml of the adsorbent arid equilibrated with Tris buffer pH 7.4. Standard phosphate solution or plasma was pumped throügh the columns by means of a roiler pump (Intusomat, B. Braun Melsungen AG) at a flow rate of l ml/min. After collectipn of 4 rril pre-eluate, samples were drawn from the eluate ,at various time interväls. Phosphate, iron, calcium, glucose, heparin, and enẑ ymes were determined in the samples. For the analysis of plasma the reservoir was kept in a shaking bath at 37 °C.
To determine the maximal binding eapacity, aqueous phosphate solution, blood or plasma was circulated for 18 h at a rate pf l ml/ min thrpugh a column containing 3 ml adsorbent. The material was then washed with 100 ml distilled water to remove unbound phosp hate, dried at 60 °C> and analysed for phosphate äs described above.
For adsorption experiments with blood, a cylindrical Makroion™ cartridge (volume: 250 ml) was used. The column inlet and outlet were closed by sieves with a mesh size of 94
. EDTA-stabilized blood (500 ml) was circulated throügh the cartridge at a flow rate of 100 ml/min. The blood reservoir was kept in a shaking bath at 37 °C.
In vivo perfusion tests
In vivo experiments were carried out with locally anaesthetized female sheep in the laboratory of the Experimental Surgery deparl· ment (B. Braun Melsungen AG) according to an officially licensed protocol. Cartridges (250 ml) were slurry-packed with adsorbent and integrated in a dialysis circulation unit (HD secura, B. Braun Melsungen AG). Equilibration of the adsorbent and prewashing of the tubing System was carried out by circulating with 9 g/l sodium Chloride solution. A conventional dialysis solution (acetate concentrate, 35 mmol/1) was used. To prevent fibrin clotting during therapy, heparin (10000 lU/h) was administered to the sheep.
Results
Characterization of the adsorbent
Reaction of the insoluble, crosslinked dextran matrix with a concentrated FeCl 3 solution at high pH led to an iron uptake of 160-210 g/kg ünder our Standard reaction conditions. A stable product was obtained after washing with deionized water to neutrality. Drying, heat Sterilization, prolonged passage of phosphate Solutions, or contact with blood did not result in any leaching or loss of iron from the material, Although the uniform surface of the untreated gel beads became rough and vaulted in the iron-coated spheres ( fig. 1 ) the material could without difficulty be handled in flow-through columns or cartridges. ray photoelectron spectroscopy (ESCA), were 710.5 eV (Fe 2 p3/2) and 535.4 eV (Oi S ), respectively, in close agreement with the values found in Fe(OH) 3 and other reference compounds (21) . M ssbauer and magnetic susceptibility measurements revealed the presence of high-spin Fe phate binding capacity (tab. 1). Higher amounts of iron, produced by repeated treatment of the adsorbent in FeCl 3 solution, did not raise the phosphate binding capacity. In equilibrium binding experiments, sterile adsorbents coated with 210 g/kg iron typically bound 250 mmol (7.7 g) Pj per kg or 90 mmol (2.6 g) P { per litre adsorbent. These values were obtained by equilibrating 3 ml of sterilized adsorbent in a column for 18h with 500 ml circulating phosphate Standard solution, followed by removal of unbound inorganic phosphate by washing the column with 50 ml distilled water. Absorption of phosphate from an aqueous solution onto the iron-dextrari complex could also be monitored by 31 
P-NMR (not shown).
The phosphate adsorption capacity was generally reduced about 30% after heat sterilization ( fig. 2) . On the other hand, heat sterilization ppears to lead to a stabilized iron(III) oxide-hydroxide modified dextran at acidic pH vaiues. Thus, the sterilized adsorbent does not liberale iron even around pH 2.
Perfasion of 3 ml adsorbent (950 mg dry weight, iron content 157 g/kg) with 100 ml human plasma resulted in the binding of 2.04 g phosphorus per litre gel which corresponds to a 74% reduction of the phosphate content ( fig. 3) . No alterations of the protein and iron(III) concentration, or of distinct enzyme activities were observed during the treatment. The profile of the elimination curve shows that additional phosphate can be adsorbed when higher blood phosphate concentrations are present.
Investigation of the haemocompatibility of the adsorbent in a 250 ml-cartridge showed that the phosphate concentration of circulating whole blood decreased from 1.1 mmol/1 to 0.09 mmol/1 (3.4 mg/dl to 0.3 mg/dl PI). At a flow rate of 100 ml/min, a pressure of 80 mbar was built up. Even after 25 circulations the material did not induce haemolytic reactions, and there were no significant alterations in common blood quantities äs shown in table 2.
• \ Elimination of calcium ions
The behaviour towards calcium ions was determined by perfusing the adsorbent in a 3 ml column with 100 ml of human serum, heparinized plasma or standardized calcium solution (fig. 4) . Calcium was only bound to the adsorbent in the presence of phosphate but not in phosphate-free solution. A molar ratio of calcium and phosphate elimination of approximately l : l was reached when both concentrations were varied.
In vivo experiments
The iron(III)oxide-hydroxide dextran adsorbent was tested in extracorporeal apheresis experiments with sheep. Laboratory data are reported in Fig. 3 Elimination of phosphate from 100 ml human plasma (initial P content, 2.8 mg). Conditions äs in Fig. 2. as handling, flow rate, pressure, and the influence on important quaiitities such as haemocompatibility, whole blood count, and the concentrations of phosphate, calcium and iron. The application of the adsorbent caused an efficient and significant decrease of the postcartridge phosphate concentratiqn from 1.93 mmol/1 (6,0 mg/dl) to 0.06 mmol/1 (0.2 mg/dl) P f at the end of treatment (l h dialysis). There was neither an increase iii the iron nor a decrease in the calcium concentration öf the blood during treatnient with conventional dialysis solutions containing calcium. By appropriate dosage of heparin, the flow rate and pressure could be kept at normal levels without inducing haemolysis or significant alterations of the blood cells. Only thrombocytes were feduced during treatment. This was possibly due to some fibrin clotting which was not observed in in vitro experiments.
Discussion
Patients with kidney diseases, especially those with chronic renal failure, who have been on haemodialysis for a lofig time, often have Symptoms ässociated with highly elevated concentrations of inorganic phosphate in the blood. Lafge amounts of phosphate äbove normal levels (0.6-1.3 mmol/1) result in a decrease of calcium ion concentration which in turn induces the parathyroid to secrete an excess amount of parathyroid hormone. The hormone increase and the inability of the diseased kidney to hydroxylate 25-hydroxycholecalciferol to the active forms of vitamin D are the principal biochemical factors underlying most of the related Symptoms (22, 23) . In the case of chronic renal failure the filtration rate of glomeruli is less than 8-10 ml/min. Pathological phosphate concentrations ranging between 2.25 and 3 mmol/1 normally decrease to 1.3 -1.6 mmol/1 after haemodialysis (24) . In this context, it has recently been shown that extracorporeal elimination of phosphate is more effective usihg Standard dialysers than high-fluxdialysers (7! Eisenhauer, C. Ronco, unpublished). This effect is due to the limited phosphate concentration in the blood. Thus, the intravascular phosphate concentration rather than the clearaiice seems to be rate-limiting. The phosphate clearance, for exatnple of the Diacap capillary dialyser (B. Braun, Melsungen, Germany) lies between 93 and 150 ml/min when pumping blood at 200 ml/min and dialysis solution at 500 ml/min.
The phosphate intake of a patient is 32 mmol per day or about 224 mmol per week. During one dialysis Session about 32 mmol phosphate are normally eliminated (4). These rates of removal äfe insüfficient to prevent hyperparathyroidism. Tab. Blood was pässed through a cartridge containing 250 ml of phosphate adsorbent; flow rate, 70^90 ml/min. most patients with en&stage renal failure and rnany with moderate tp marked renal insufficiency require phosphate binders. Their applicätion is necessary to avoid skeletal pain, changes in bone mineralization, spontaneous ftactures, and calcium phosphate-like deposits in soft tissues and blood vessels (25, 26) . In recent years it has been reported that the most seriously intoxicated patients had been treated with dialysing fluid containing high concentrations of aluminum and phosphate binders containing aluminum (27) (28) (29) . The dialysis dementia syndrome was related to the increased concentration of aluminum in the plasma and in the brain tissue (30, 31) . For that reason many authors propagated the oral applicätion of aluminum-free compounds such äs calcium carbonate or calcium acetate (32, 33) . However, medication with the latter is associated with gastro-intestinal Problems and a high risk of hypercalcaemia (10) .
From these considerations it follows that a more effective and safer treatment of hyperphosphataemia can be achieved by extending the total dialysis time and by the optional applicätion of aluminum-free phosphate binders. Prolonging dialysis time, however, is not applicable äs it additionally Stresses the patient. Instead, the desired systemic reduction of phosphate should be achieved by using, in addition to and simultaneously with conventional haemodialysis, an adsorbent which specifically removes the excess phosphate. To be clinically usefül, such an adsorbent has to be integrated into the extracorporeal perfusion System and must be capable of eliminating phosphate directly from whole blood. Extracorporeal removal of excess inorganic phosphate is especially of interest for patients who refuse phosphatelowering medication because of personal discomfort. For a potentially chronic applicätion such a procedure must be free of even minor side effects. In addition, it should permit a blood flow of at least 100 ml/min.
We therefore recently developed a new phosphate binding agent (13) . A porous, highly crosslinked and insoluble dextran was complexed with polynuclear iron oxidehydroxide (FeOOH) centres. With the exception of a non-porous agarose chromatography support described by Hjerten (34) , only soluble complexes between iron hydroxide and mono-and polysaccharides have previously been prepared (35, 36) . Such complexes, e. g. with polymaltose (Ferrum-Hausmann™), are used for the therapeutic treatment of iron deficiency anaemias in humans and animals (37, 38) . Structural studies on soluble iron oxide-hydroxide complexes showed that they form chainlike, polynuclear condensation products (39) and that iron is present äs tetragonal ß-FeOOH (40) .
Structure characterization of the newly synthesized, amorphous, insoluble iron-dextran complexes is less complete. Nevertheless, the ESCA and Mössbauer spectra confirm that only high-spin ferne irons with oxygen ligarids (sugar OH groups, water, hydroxide ions, -bridges) are present. The most typical iron mass Proportion of about 200 g/kg found in the dry material suggests that each iroii(III) centre is statistically coordinated to one glucose moiety (glucose-Fe(OH) 3 , Fe = 195 g/kg). In fact, the magnetic susceptibility and its temperature dependence, measured in the ränge from 4 to 300 K, are very similar to a soluble, stoichiometric Fe-glucose complex (35) .
A few reports describe the interaction of phosphate with iron-containing compounds (34, 37, 41, 42) . Addition of phosphate, even in small amounts, may lead to strong effects, for example increased viscosity in iron-polymaltose Solutions (37) . FeOOH-modified non-porous agarose has been saturated with phosphate and used in this form äs ion exchanger for the chromatography of proteins (34).
The adsorbent described here is, to our knowledge, the first one that specifically removes inorganic phosphate and which fulfils the criteria for an application in an extracorporeal blood perfiision System. The high binding capacity of the adsorbent guarantees an efficient elimination of phosphate during haemodialysis. The pathological excess of about 130 mmol of phosphate per week in patients with end^stage renal failure, for example, would be elimiriated düring the common three dialysis sessions by an additional, integrated phosphate adsorption apheresis using a cartridge packed with 450 ml of the new adsorbent.
On-line apheresis has the extra advantage that it can be precisely controlled by adjusting the eartridge size (i. e. total phosphate binding capacity) to the blood völume. Material costs can be significantly reduced by repeated regeneration and re^use of the adsorbent. Iii this context it was shown that regeneration by a simple treatment with NaOH did not cäuse a decrease of the phosphate binding capacity. The described in vivo experiments with sheep revealed no side efFects. Concomitant calcium depletion can be compensated by dialysis. Ideally, it may be expected that oral phosphate binders can be avoided and no other measures have to be taken.
In conclusion, the newly developed iron(III) oxide-hydroxide modified dextran is suitäble for the selective elimination of inorganic phosphate from whole blood. The excellent phosphate elimination capacity and blood compatibility make it attractive for the extracorporeal treatment of hyperphosphataemia in acüte and chronic renal failure.
